LABU Advances +25% Over 30 Days as Biotech Momentum Builds

Key Takeaways

• LABU, a leveraged exchange-traded fund (ETF) seeking triple the daily return of the S&P Biotechnology Select Industry Index, advanced roughly 25% over the trailing 30-day period.
• The move extends a broader uptrend, with the fund up approximately 81% over the last quarter.
• Because the underlying index is equal-weighted, no single holding dominates; strength has been broad-based across small- and mid-cap biotech developers.
• Easing interest-rate expectations, rising merger-and-acquisition (M&A) activity, and positive clinical catalysts have supported risk appetite across the sector.
• As a 3x leveraged fund, LABU amplifies gains and losses and can diverge from three times the index return over multi-week periods due to daily compounding.

LABU Overview and Portfolio Exposure

The Direxion Daily S&P Biotech Bull 3X Shares seeks daily investment results, before fees and expenses, equal to 300% of the daily performance of the S&P Biotechnology Select Industry Index. The fund, which debuted in 2015, uses swap agreements and cash and treasury instruments to achieve its leveraged exposure rather than buying every index constituent outright.

The index itself tracks the biotechnology segment of the U.S. market using an equal-weighting methodology, which limits single-stock concentration. LABU reports roughly 170 positions including swaps and cash instruments, with assets under management (AUM) of approximately $680 million and a net expense ratio near 0.96%. Sector exposure is effectively concentrated in healthcare and biotechnology.

Top equity holdings are each small weights, typically near 1% to 1.5%, and include Apellis Pharmaceuticals (APLS), Revolution Medicines (RVMD), Travere Therapeutics (TVTX), Arrowhead Pharmaceuticals (ARWR), Moderna (MRNA), Twist Bioscience (TWST), and Viking Therapeutics (VKTX). This diversified, equal-weighted structure means the fund's recent ETF performance has been driven by sector-wide momentum rather than any single stock. I also checked this using Tickeron’s AI Screener to see how the holdings compare to peers in the space.

LABU Price Performance: Last 30 Days vs. Quarter

Over the trailing 30 days, LABU rose from an adjusted closing level near $254 to roughly $317, a gain of about 25%. The advance was volatile rather than linear, with sharp pullbacks followed by rapid recoveries, consistent with a leveraged product tracking high-beta small-cap names.

The quarterly picture is even stronger. Approximately three months earlier, the fund closed near $175, meaning LABU climbed roughly 81% over the last quarter. This longer-term move reflects a sustained recovery in the biotech complex after an extended period of weakness, with momentum broadening across therapeutic categories.

What Drove LABU Price in the Last 30 Days

The recent surge reflects a combination of sector rotation and improved risk appetite. Small- and mid-cap biotech companies are heavily dependent on external financing, making the group acutely sensitive to interest-rate expectations. As market pricing shifted toward a more accommodative policy path, long-duration biotech names rallied broadly, and the leveraged structure multiplied that move.

Renewed M&A activity also underpinned sentiment, as larger pharmaceutical companies continued to acquire clinical-stage assets at premium valuations. Positive clinical trial readouts across oncology, metabolic disease, and RNA-based therapies added idiosyncratic catalysts across the index's many holdings. Because the index is equal-weighted, gains among dozens of small developers collectively lifted the benchmark, which in turn amplified LABU's daily return.

What Drove LABU Performance Over the Last Quarter

The quarterly trend reflects a longer-running recovery in biotech after a prolonged drawdown. Institutional fund flows back into the sector, a friendlier rate backdrop, and a steady cadence of dealmaking and data catalysts drove the equal-weighted index higher. Larger, more liquid holdings such as Moderna, Twist Bioscience, and Revolution Medicines contributed alongside smaller developers, underscoring the breadth of the move.

Compounding effects are worth noting. Because LABU resets its exposure daily, a sustained trend can produce a multi-week return that differs meaningfully from a simple three-times multiple of the index's cumulative move. In strong trending markets this can work in the fund's favor, but it also heightens volatility in both directions.

LABU ETF Outlook: What Investors Should Watch Next

Several themes are likely to shape LABU's trajectory in the months ahead. Interest-rate expectations remain the dominant macro driver, given the sector's sensitivity to financing conditions and long-duration cash flows. Inflation data and central-bank policy guidance will therefore be closely watched, as will broader economic growth signals that influence risk appetite.

At the industry level, the pace of M&A, the volume of late-stage clinical readouts, and regulatory decisions from the FDA will continue to set the tone for the underlying index. Ongoing innovation in weight-loss and metabolic therapies, oncology, and genetic medicines provides a pipeline of potential catalysts. Investors should also monitor capital flows into and out of leveraged biotech products, which can amplify short-term moves. As a 3x daily-reset instrument, LABU carries elevated risk and is designed for short-term tactical use rather than buy-and-hold strategies. From what I see, keeping an eye on these macro and sector-specific factors remains essential.

AI Screener

One resource I turn to regularly when evaluating leveraged products and sector trends is Tickeron’s AI Screener. The platform helps scan for technical indicators, volatility measures, fundamentals, and AI-driven signals across thousands of securities. It has proven useful for identifying momentum in areas like biotechnology without manual effort across multiple screens.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Jimmy Landsman|Expert

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume